Evidence map›Paper›PMID 42633286›Full record

ArticleMolecular therapy. Nucleic acids2026

SafeSense: An open-access safety atlas for antisense oligonucleotides adverse events in human.

Noam Vaknin, Aviv Ziv, Tom Chernobylsky, Sharon Avkin-Nachum, Gideon Rechavi, Dan Dominissini, Nofar Mor, N=1 Collaborative

Abstract read
In one paragraph

Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Noam VakninCancer Research Center and Wohl Institute for Translational Medicine, Tel Hashomer, Ramat Gan, Israel.
Aviv ZivCancer Research Center and Wohl Institute for Translational Medicine, Tel Hashomer, Ramat Gan, Israel.
Tom ChernobylskyCancer Research Center and Wohl Institute for Translational Medicine, Tel Hashomer, Ramat Gan, Israel.
Sharon Avkin-NachumCancer Research Center and Wohl Institute for Translational Medicine, Tel Hashomer, Ramat Gan, Israel.
Gideon RechaviCancer Research Center and Wohl Institute for Translational Medicine, Tel Hashomer, Ramat Gan, Israel.
Dan DominissiniCancer Research Center and Wohl Institute for Translational Medicine, Tel Hashomer, Ramat Gan, Israel.
Nofar MorCancer Research Center and Wohl Institute for Translational Medicine, Tel Hashomer, Ramat Gan, Israel.
N=1 Collaborative

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antisense oligonucleotides (ASOs) therapeutics are a powerful class of RNA-targeted therapy, with applications ranging from traditional development pipelines to individualized drugs. ASO therapeutics share common chemical architecture, including modifications and structure, thus enabling cross-program safety analyses, which provide insights into class-specific safety liabilities. Here, we present SafeSense, a safety atlas specifically dedicated to ASOs, integrating adverse event (AE) in human, encompassing data for 112 ASOs, curated in collaboration with the preclinical working group of the

Indexed as

adverse eventsantisense oligonucleotidefully modifiedgapmerMT: oligonucleotides: therapies and applicationspharmacovigilanceSafeSensesafety

Identifiers

PMID42633286
PMCPMC13499347

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.